

10/561,838

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10561838h.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss

SAMPLE SEARCH INITIATED 12:59:07 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 832 TO ITERATE

10/923,271

100.0% PROCESSED 832 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 14910 TO 18370
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.49	0.71

FILE 'CAPLUS' ENTERED AT 12:59:21 ON 03 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jun 2010 VOL 152 ISS 23
FILE LAST UPDATED: 2 Jun 2010 (20100602/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 5 L2

=> s l3 and py<2005

25158280 PY<2005

L4 1 L3 AND PY<2005

=> d ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 5.81 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:529133 CAPLUS

DOCUMENT NUMBER: 131:157711

TITLE: Preparation of pyridinecarboxylates and analogs as cholesteryl ester transfer protein inhibitors

INVENTOR(S): Lee, Len F.; Glenn, Kevin C.; Connolly, Daniel T.; Corley, David G.; Flynn, Daniel L.; Hamme, Ashton; Hegde, Shridhar G.; Melton, Michele A.; Schilling, Roger J.; Sikorski, James A.; Wall, Nancy N.; Zablocki, Jeffrey A.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: PCT Int. Appl., 327 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9941237	A1	19990819	WO 1999-US1871	19990211 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9932854	A	19990830	AU 1999-32854	19990211 <--
US 6605624	B1	20030812	US 2000-600870	20001211 <--
US 20040038939	A1	20040226	US 2003-403903	20030331 <--
US 6794396	B2	20040921		
US 20040220231	A1	20041104	US 2004-852975	20040525 <--
PRIORITY APPLN. INFO.:			US 1998-74586P	P 19980213
			WO 1999-US1871	W 19990211
			US 2000-600870	A3 20001211
			US 2003-403903	A3 20030331
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):	MARPAT 131:157711			
GI				



AB Title compds. [I; R², R⁶ = H, OH, (fluoro)alkyl, alkoxy, etc.; R³ = OH, CHO, alkoxycarbonyl, (hetero)arylcabonyl, etc.; R⁵ = H, halo, alkyl, alkoxy, etc.; R⁶ = H, halo, alkyl, alkoxy(carbonyl), etc.] were prepared

Thus, CF₃C(NH₂):C(CO₂Me)COMe was refluxed with Ac₂O/HC(OMe)₃ and the product converted in 2 steps to I (R₂ = CF₃, R₃ = CO₂Me, R₄ = OCHMe₂, R₅ = R₆ = H). Data for biol. activity of I were given.


IT 237759-21-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinecarboxylates and analogs as cholesteryl ester transfer protein inhibitors)

RN 237759-21-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-(difluoromethyl)-4-(2-methylpropyl)-5-[(2-pyridinylmethyl)thio]-6-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.12	9.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.85	-0.85

FILE 'REGISTRY' ENTERED AT 13:00:37 ON 03 JUN 2010
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JUN 2010 HIGHEST RN 1226851-61-1
 DICTIONARY FILE UPDATES: 2 JUN 2010 HIGHEST RN 1226851-61-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s ll sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:00:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 16631 TO ITERATE

100.0% PROCESSED 16631 ITERATIONS 155 ANSWERS
SEARCH TIME: 00.00.01

L5 155 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	191.54	201.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.85

FILE 'CAPLUS' ENTERED AT 13:00:58 ON 03 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jun 2010 VOL 152 ISS 23
FILE LAST UPDATED: 2 Jun 2010 (20100602/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15

L6 22 L5

=> s 16 and py<2005

25158280 PY<2005

L7 9 L6 AND PY<2005

=> d 1-9 ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 52.29 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:756691 CAPLUS

DOCUMENT NUMBER: 141:260553

TITLE: Preparation of compounds having 4-pyridylalkylthio group as inhibitors of angiogenesis and vascular permeability

INVENTOR(S): Honda, Takahiro; Tajima, Hisashi; Sasabuchi, Yoshimasa; Kawashima, Kenji; Okamoto, Kazuyoshi; Yamamoto, Minoru; Ban, Masakazu

PATENT ASSIGNEE(S): Santen Pharmaceutical Co. Ltd., Japan

SOURCE: PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078723	A1	20040916	WO 2004-JP2812	20040305 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005232149	A	20050902	JP 2004-109503	20040305
EP 1602647	A1	20051207	EP 2004-717833	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 20060194836	A1	20060831	US 2005-548283	20050901
US 7534802	B2	20090519		
US 20090286786	A1	20091119	US 2009-381290	20090310
JP 2010116403	A	20100527	JP 2010-2879	20100108
PRIORITY APPLN. INFO.:			JP 2003-62042	A 20030307
			JP 2004-11602	A 20040120
			JP 2004-109503	A3 20040305
			WO 2004-JP2812	W 20040305


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:260553


GI



- AB Title compds. e.g. I (R1, R2 = H, alkyl, cycloalkyl, Ph, substituted Ph, heteroaryl, etc.), useful as as inhibitors of angiogenesis and vascular permeability, are prepared Thus, stirring 2-(4-pyridylmethylthio)pyridine-3-carboxylic acid with 4-chloroaniline in DMF in the presence of N,N-diisopropylethylamine and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate at room temperature for 3 h gave 91% N-(4-chlorophenyl)-2-(4-pyridylmethylthio)pyridine-3-carboxamide (II). II showed angiogenesis inhibitor activity at 20 µg/mL. Formulations containing I were given.
- IT 754220-09-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of compds. having 4-pyridylalkylthio group as inhibitors of angiogenesis and vascular permeability)
- RN 754220-09-2 CAPLUS
- CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(4-pyridinylmethyl)thio]-
 (CA INDEX NAME)



IT 754218-68-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of compds. having 4-pyridylalkylthio group as inhibitors of
 angiogenesis and vascular permeability)
 RN 754218-68-3 CAPLUS
 CN 2-Pyridinecarboxylic acid, 3-[(4-pyridinylmethyl)thio]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (14 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER: 2003:532638 CAPLUS

DOCUMENT NUMBER: 139:101146

TITLE: Preparation of benzyl or heterocyclylmethyl phenyl or
 heterocyclyl sulfones as β -amyloid protein
 production/secretion inhibitors

INVENTOR(S): Yasukochi, Takanori; Ito, Masayuki; Kubota, Hideki;
 Miyauchi, Satoshi; Saito, Masaki

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 540 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055850	A1	20030710	WO 2002-JP13792	20021227 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2471943	A1	20030710	CA 2002-2471943	20021227 <--
AU 2002367147	A1	20030715	AU 2002-367147	20021227 <--
EP 1466898	A1	20041013	EP 2002-790937	20021227 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			

CN 1585746	A	20050223	CN 2002-827790	20021227
CN 100562516	C	20091125		
RU 2304140	C2	20070810	RU 2004-122915	20021227
JP 4329905	B2	20090909	JP 2003-556382	20021227
KR 927304	B1	20091118	KR 2004-709960	20021227
US 20050234109	A1	20051020	US 2004-500156	20040625
US 7399775	B2	20080715		
US 20070293495	A1	20071220	US 2007-829533	20070727
PRIORITY APPLN. INFO.:			JP 2001-395701	A 20011227
			WO 2002-JP13792	W 20021227
			US 2004-500156	A3 20040625


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 139:101146

AB Novel compds. having various substituents as represented by the following general formula R1(R2)(R3)C-X-R4, salts thereof, and solvates of the same [wherein X = S, SO, SO2; R1 = CR5R6R7, NR8R9, X1R10, X2R11; wherein R5, R6, R7 = halo, cyano, NO2, -Q51-Q52-Q53-Q54; Q51, Q53 = single bond, CO, S(O), SO2, COCO, COC(S), C(S)C(S); Q52 = single bond, O, ON(A51), ON(COA51), N(A51), N(COA51), N(COA51), N(CON(A51)(A52)), N(OA51), N(N(A51A52)), N(A51)N(A52), N(COA51)N(A52), N(A51)-O, N(COA51)-O, S, N:N, C(A51):N, C(A51):N-O, C(A51):N-N(A52), N:C(A51), O-N:C(A51), N(A51)-N:C(A52), C(:NA51)-N(A52); Q54 = A53, OA53, N(A53)(A54), SA53, NA54-OA53, NA55-N(A53)(A54), O-N(A53)(A54); wherein A51, A52, A53 = H, (un)substituted hydrocarbyl or heterocyclyl; R2, R3, R4, R8, R9, R10, R11 = -Q51-Q52-Q53-Q54 defined in R5-R7; X1 = O, S; X2 = SO, SO2; or R1 and R2 or R3 and R4 are combined together to form (un)substituted cyclohydrocarbyl or heterocyclyl] are prepared. These compds. have an effect of inhibiting the production/secretion of a β -amyloid protein and are useful for the prevention or treatment of diseases caused by unusual production/secretion of β -amyloid, in particular Alzheimer's disease or Down's syndrome. Thus, a solution of 100 mg 2,5-dichloro-4-[(4-chlorophenylthio)-(2,5-difluorophenyl)methyl]pyridine (preparation given) and 200 μ L morpholine in 1.0 mL 1,4-dioxane was stirred at 100° for 2 days to give 4-[5-chloro-4-[(4-chlorophenylthio)-(2,5-difluorophenyl)methyl]pyridin-2-yl]morpholine which (90 mg) was dissolved in 12 mL MeOH, treated with 60 mg ammonium molybdate tetrahydrate [(NH4)6Mo7O24.4H2O] and 6 mL 30% H2O2, and stirred for 8 h to give 83% 4-[5-chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]pyridin-2-yl]morpholine (I). I in vitro glioma cell (H4 cell) expressing human β -amyloid protein precursor protein gene (APP751 gene) with EC50 of \leq 50 nM.


IT 558465-25-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzyl or heterocyclylmethyl Ph or heterocyclyl sulfones as β -amyloid protein production/secretion inhibitors for treatment or preparation of Alzheimer's disease or Down's syndrome)

RN 558465-25-1 CAPLUS


CN Pyridine, 2-chloro-5-[(3-chloro-4-pyridinyl)(2,5-difluorophenyl)methyl]thio]- (CA INDEX NAME)



IT 558465-26-2P 558465-27-3P 558465-49-9P
 558465-50-2P 558465-75-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of benzyl or heterocyclymethyl Ph or heterocyclyl sulfones as
 β -amyloid protein production/secretion inhibitors for treatment or
 preparation of Alzheimer's disease or Down's syndrome)
 RN 558465-26-2 CAPLUS
 CN Pyridine, 2-chloro-5-[(3-chloro-4-pyridinyl)(2,5-
 difluorophenyl)methyl]sulfonyl- (CA INDEX NAME)




RN 558465-27-3 CAPLUS
 CN Pyridine, 5-[(3-chloro-4-pyridinyl)(2,5-difluorophenyl)methyl]sulfonyl-2-
 fluoro- (CA INDEX NAME)



RN 558465-49-9 CAPLUS
 CN Pyridine, 2-chloro-5-[(3,6-dichloro-2-pyridinyl)-4-pyridinylmethyl]thio]-


10/923,271

(CA INDEX NAME)




RN 558465-50-2 CAPLUS

CN Pyridine, 3,6-dichloro-2-[[[(6-chloro-3-pyridinyl)sulfonyl]-4-pyridinylmethyl]- (CA INDEX NAME)



RN 558465-75-1 CAPLUS

CN Pyridine, 2-chloro-5-[[[(3,6-dichloro-2-pyridinyl)sulfonyl]-4-pyridinylmethyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:171629 CAPLUS

DOCUMENT NUMBER: 136:226767

TITLE: Cephalosporin antibiotics and prodrugs thereof


INVENTOR(S): Glinka, Tomasz W.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017854	A2	20020307	WO 2001-US26628	20010823 <--
WO 2002017854	A3	20020613		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20020115650	A1	20020822	US 2001-925217	20010808 <--
US 6599893	B2	20030729		
CA 2420871	A1	20020307	CA 2001-2420871	20010823 <--
AU 2001088420	A	20020313	AU 2001-88420	20010823 <--
EP 1333836	A2	20030813	EP 2001-968147	20010823 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001013634	A	20040203	BR 2001-13634	20010823 <--
ZA 2003001391	A	20040220	ZA 2003-1391	20010823 <--
JP 2004507481	T	20040311	JP 2002-522829	20010823 <--
NZ 524438	A	20050826	NZ 2001-524438	20010823
RU 2281948	C2	20060820	RU 2003-108734	20010823
AU 2001288420	B2	20060928	AU 2001-288420	20010823
TW 283681	B	20070711	TW 2001-90121362	20010829
NO 2003000931	A	20030429	NO 2003-931	20030227 <--
MX 2003001782	A	20041101	MX 2003-1782	20030227 <--
PRIORITY APPLN. INFO.:			US 2000-229174P	P 20000829
			WO 2001-US26628	W 20010823

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 136:226767
 GI




AB The present invention relates to novel cephalosporin antibiotics, prodrugs thereof and pharmacol. acceptable salts of either, which are active against a wide spectrum of bacteria that are resistant to present clin. β -lactam antibiotics. E.g., I among many other similar cephalosporin derivs. was prepared Compds. were evaluated for antimicrobial activity against a panel of bacterial strains, mainly *Staphylococcus aureus* and the compds. were also tested in mice challenged i.p. with a bacterial suspension of *S. aureus*.

IT 315181-86-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cephalosporin antibiotics and prodrugs)

RN 315181-86-3 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-3-[[3-[[[(2-amino-3-pyridinyl)thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)- (CA INDEX NAME)]

Absolute stereochemistry.
 Double bond geometry as shown.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:780048 CAPLUS
 DOCUMENT NUMBER: 134:71401
 TITLE: SAR studies of anti-MRSA non-zwitterionic
 3-heteroarylthiocephems
 AUTHOR(S): Glinka, T. W.; Cho, A.; Zhang, Z. J.; Ludwikow, M.;
 Griffith, D.; Huie, K.; Hecker, S. J.; Dudley, M. N.;
 Lee, V. J.; Chamberland, S.
 CORPORATE SOURCE: Microcide Pharmaceuticals, Mountain View, CA, USA
 SOURCE: Journal of Antibiotics (2000), 53(10),
 1045-1052

PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:
GI


CODEN: JANTAJ; ISSN: 0021-8820
Japan Antibiotics Research Association
Journal
English



AB Structure activity relationship studies in a series of 3-heteroarylthio substituted cephalosporins established that high activity against methicillin-resistant *Staphylococcus aureus* (MRSA) can be achieved with various heteroaryl substituents. Early results showed that highly lipophilic 3-heteroarylthio substituents, which were necessary for anti-MRSA activity, caused high affinity of such cepems toward serum proteins. The authors earlier published efforts described discovery of zwitterionic cepems MC-02,331 and RWJ-54428 (MC-02,479), where serum binding was reduced by employing basic, pos. charged functionalities attached to the 3-heteroarylthio substituent. In order to avoid low solubility problems associated with most such zwitterionic cephalosporins a wide variety of non-basic heteroaryl substituents, e.g. I, was tested (non-zwitterionic cepems are more easily formulated as water soluble sodium salts for i.v. administration). Considerable reduction in serum binding was obtained in some analogs while maintaining high anti-MRSA potency.

IT 315181-83-0P 315181-86-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure activity relationship studies of anti-methicillin-resistant *Staphylococcus aureus* non-zwitterionic 3-heteroarylthiocephems)
RN 315181-83-0 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-8-oxo-3-[[3-[[3-pyridinylthio)methyl]-4-pyridinyl]thio]-, (6R,7R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 315181-86-3 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[(2Z)-2-(2-amino-5-chloro-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-3-
[[3-[[(2-amino-3-pyridinyl)thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)-
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:529133 CAPLUS

DOCUMENT NUMBER: 131:157711

TITLE: Preparation of pyridinecarboxylates and analogs as
cholesteryl ester transfer protein inhibitors

INVENTOR(S): Lee, Len F.; Glenn, Kevin C.; Connolly, Daniel T.;


Corley, David G.; Flynn, Daniel L.; Hamme, Ashton;
Hegde, Shridhar G.; Melton, Michele A.; Schilling,
Roger J.; Sikorski, James A.; Wall, Nancy N.;
Zablocki, Jeffrey A.

PATENT ASSIGNEE(S):
SOURCE: G.D. Searle and Co., USA
PCT Int. Appl., 327 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9941237	A1	19990819	WO 1999-US1871	19990211 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9932854	A	19990830	AU 1999-32854	19990211 <--
US 6605624	B1	20030812	US 2000-600870	20001211 <--
US 20040038939	A1	20040226	US 2003-403903	20030331 <--
US 6794396	B2	20040921		
US 20040220231	A1	20041104	US 2004-852975	20040525 <--
PRIORITY APPLN. INFO.:			US 1998-74586P	P 19980213
			WO 1999-US1871	W 19990211
			US 2000-600870	A3 20001211
			US 2003-403903	A3 20030331
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 131:157711		
GI				




AB Title compds. [I; R2, R6 = H, OH, (fluoro)alkyl, alkoxy, etc.; R3 = OH, CHO, alkoxycarbonyl, (hetero)arylcarbonyl, etc.; R5 = H, halo, alkyl, alkoxy, etc.; R6 = H, halo, alkyl, alkoxy(carbonyl), etc.] were prepared Thus, CF3C(NH2):C(CO2Me)C(OMe)3 was refluxed with Ac2O/HCl(OMe)3 and the product converted in 2 steps to I (R2 = CF3, R3 = CO2Me, R4 = OCHMe2, R5 = R6 = H). Data for biol. activity of I were given.

IT 237758-70-2P 237758-71-3P 237759-21-6P
237759-29-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinecarboxylates and analogs as cholesteryl ester
transfer protein inhibitors)


RN 237758-70-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-(difluoromethyl)-5-[[[6-(difluoromethyl)-5-(methoxycarbonyl)-4-(2-methylpropyl)-2-(trifluoromethyl)-3-pyridinyl]methyl]thio]-4-(2-methylpropyl)-6-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 237758-71-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-(difluoromethyl)-5-[[[6-(difluoromethyl)-5-(methoxycarbonyl)-4-(2-methylpropyl)-2-(trifluoromethyl)-3-pyridinyl]carbonyl]thio]-4-(2-methylpropyl)-6-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




RN 237759-21-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-(difluoromethyl)-4-(2-methylpropyl)-5-[(2-pyridinyl)methyl]thio]-6-(trifluoromethyl)-, methyl ester (CA INDEX NAME)


TR, TT, UA, UG, US, UZ, VN, YU, ZW
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6329372 B1 20011211 US 1999-237060 19990126 <--
 AU 9924320 A 19990809 AU 1999-24320 19990127 <--
 EP 1051399 A1 20001115 EP 1999-903798 19990127 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2002501051 T 20020115 JP 2000-528542 19990127 <--
 US 20020035127 A1 20020321 US 2001-964161 20010926 <--
 GB 1998-1674 A 19980127
 GB 1998-26669 A 19981203
 US 1999-237060 A1 19990126
 WO 1999-GB279 W 19990127
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 131:116520
 AB Phenylalanine derivs. 4-[R1(Alk1)rLls]C6H2RaRb(Alk2)mCHRR2NR3COHet [R is a
 carboxylic acid or derivative; R1 = H, OH, alkoxy or optionally substituted
 cycloaliph., polycycloaliph., heterocycloaliph., polyheterocycloaliph.,
 arom, or heteroarom. group; Alk1 = optionally substituted aliphatic or
 heteroaliph. chain; L1 is a linker atom or group; r, s = 0, 1; Ra, Rb =
 -L2(CH2)pL3Rcq, where L2, L3 = a covalent bond or linker atom or group; p
 = 0, 1; q = 1-3; Rc = H, halo, alkyl, OH, alkoxy, etc.; Alk2 = alkylene; m
 = 0, 1; R2 = H, Me; R3 = H, alkyl; Het is an optionally substituted
 heteroarom. group] and their salts, solvates, hydrates and N-oxides were
 prepared as pharmaceutical agents. Thus,
 N-(2-chloronicotinoyl)-N'-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine
 was prepared by coupling reaction of
 N-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine Me ester with
 2-chloronicotinoyl chloride followed by ester hydrolysis. Title compds.
 were tested for inhibition of integrin-dependent cell adhesion and
 generally have IC50 values in the $\alpha 4\beta 1$ and $\alpha 4\beta 7$
 assays of $1\mu\text{M}$ and below.
 IT 232617-68-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylalanine derivs. as pharmaceutical agents)
 RN 232617-68-4 CAPLUS
 CN L-Phenylalanine, 4-[[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-N-[[3-[(3-
 pyridinylmethyl)thio]-4-pyridinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS
RECORD (27 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2010 ACS on SIN
ACCESSION NUMBER: 1998:779062 CAPLUS
DOCUMENT NUMBER: 130:124973
TITLE: Selective thiophilic addition of alkyl- and
aryllithiums to dithio esters and a sulfine in the
pyridine series
AUTHOR(S): Lempereur, Claude; Ple, Nelly; Turck, Alain;
Queguiner, Guy; Corbin, Florence; Alayrac, Carole;
Metzner, Patrick
CORPORATE SOURCE: Laboratoire de Chimie Organique Fine et Heterocyclique
(UPRESA CNRS 6014), IRCOF, INSA, Mont Saint-Aignan,
76131, Fr.
SOURCE: Heterocycles (1998), 48(10), 2019-2034
CODEN: HTCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:124973
GI



AB Nucleophilic addition reactions of Me 2- and 3-pyridinedithiocarboxylate esters and sulfine (S-thiocarbonyl oxide) I with various aryl- and alkylolithiums at -78°C afforded dithio acetals or their oxides arising from a thiophilic addn of alkylolithium reagents at sulfur and subsequent alkylation or protonation at carbon. E.g., nucleophilic addition of n-butyllithium to I in anhydrous THF followed by protonation with water in THF gave the (methylthio)butylsulfanylmethylpyridine II in 90% yield after workup. The intermediate carbanions can be trapped by alkyl halides or an aldehyde. E.g., nucleophilic addition of phenyllithium to Me 3-pyridinedithiocarboxylate in THF followed by alkylation with allyl bromide gave III in 78% yield. This provides a new entry to pyridyl acyl anions, "Umpolung" synthons.


IT 219880-03-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyridinedithioacetals by regioselective nucleophilic addition

of alkylolithiums and aryllithiums to pyridinedithiocarboxylate and pyridinedithiocarboxylate S-oxides and alkylation at carbon)

RN 219880-03-2 CAPLUS

CN Pyridine, 2,6-dimethoxy-3-[[1-(methylthio)-1-(2-pyridinyl)ethyl]thio]-
(CA INDEX NAME)




OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1957:52145 CAPLUS
 DOCUMENT NUMBER: 51:52145
 ORIGINAL REFERENCE NO.: 51:9711d
 TITLE: Pyridine homolog
 INVENTOR(S): Bamford, Wm. R.
 PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	GB 758076		19560926	GB	<--
AB	See U.S. 2,769,007 (C.A. 51, 6704e).				
IT	99984-79-9P, Pyridine, 3-(4-pyridylmethylsulfonyl)-				
	RL: PREP (Preparation)				
	(preparation of)				
RN	99984-79-9 CAPLUS				
CN	Pyridine, 3-[(4-pyridinylmethyl)sulfonyl]- (CA INDEX NAME)				



L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1957:17515 CAPLUS
 DOCUMENT NUMBER: 51:17515
 ORIGINAL REFERENCE NO.: 51:3671a-e
 TITLE: 3-Pyridinesulfinic acid and derivatives
 INVENTOR(S): Goldberg, Moses W.; Teitel, Sidney
 PATENT ASSIGNEE(S): Hoffmann-La Roche Inc.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 2761866		19560904	US 1954-441949	19540707 <--
AB	The condensation of 3-pyridinesulfonyl chloride (I) with N2H4.H2O (II) and subsequent reaction with CO compds. containing 3 or more C atoms gives 3-pyridinesulfinic acid (III). Thus, treating 25 g. 100% II in 150 ml. EtOH with 30 g. I below 50°, cooling the mixture to room temperature, filtering it, adding C6H6 to the filtrate, concentrating (to remove the H2O-C6H6-EtOH ternary), filtering the concentrated solution, concentrating the filtrate to 50 ml., adding MeCN until turbid, storing overnight at 4° and filtering, yields 3-pyridinesulfonic acid hydrazide (IV), pale yellow crystals, m. 100-2°. Adding with stirring 15 ml. Me2CO (V) to 50				

g. IV in 100 ml. H₂O at a maximum temperature of 50°, diluting with 1600 ml. V, storing 3 hrs. at 4°, filtering, washing with V, and air-drying yields III, m. 161-3°. The preparation is described of the following derivs. of III (m.p. given): p-nitrophenyl 3-pyridyl sulfone, 172-4°; 1-methyl-3-(p-nitrophenylsulfonyl) pyridinium bromide-1/2H₂O, 294-6° (decomposition); 3-pyridyl 4-pyridyl sulfone (VI) 124-5°; VI.MeBr, 141-3° (decomposition); p-nitrobenzyl 3-pyridyl sulfone (VII), 204-5° (decomposition); VII.MeBr, 227-8° (decomposition); 3-(p-nitrobenzylsulfonyl)-1-propylpyridinium bromide, 217-18° (decomposition); 3-(p-nitrobenzylsulfonyl)-1-butylpyridinium bromide, 208-9° (decomposition); 3-(p-nitrobenzylsulfonyl)-1-allylpyridinium bromide, 185-6° (decomposition); 3-(p-nitrobenzylsulfonyl)-1-benzylpyridinium bromide, 208-10° (decomposition); 3-(p-nitrobenzyl-sulfonyl)-1-(p-nitrobenzyl)pyridinium bromide, 137-9° (decomposition); m-nitrobenzyl 3-pyridyl sulfone, 158-60° (decomposition); 3-(m-nitrobenzylsulfonyl)-1-methylpyridinium bromide, 225-6° (decomposition); p-nitrophenethyl 3-pyridyl sulfone, 171-3°; 3-(p-nitrophenethylsulfonyl)-1-propylpyridinium bromide, 172-4°; p-aminobenzyl 3-pyridyl sulfone, 166-8°; p- acetamidobenzyl 3-pyridyl sulfone (VIII), 181-3° (decomposition); VIII.MeBr, 225-6° (decomposition); p-chlorobenzyl 3-pyridyl sulfone (IX), 163-4°; IX.MeBr, 225-7° (decomposition); 3-pyridyl 4-pyridylmethyl sulfone (X), 150-2°; X.MeBr, 199-201° (decomposition); 2-(4-pyridyl)ethyl 3-pyridyl sulfone-2HCl (XI.2HCl), 170-2° (decomposition); XI.2MeBr, 202-3° (decomposition); XI.2PhCH₂Br.2H₂O, 183-5° (decomposition); 2-(g-pyridyl)-ethyl 3-pyridyl sulfone-2HCl (XII.2HCl, 169-71° (decomposition); XII.2MeBr 196-7° (decomposition); XII.HBr.p- O₂NC₆H₄CH₄Br, 178-9° (decomposition). The compds. are useful as antimetabolites, possessing antiniacin activity.

IT 99984-79-9P, Pyridine, 3-(4-pyridylmethylsulfonyl)-
 RL: PREP (Preparation)
 (preparation of)
 RN 99984-79-9 CAPLUS
 CN Pyridine, 3-[(4-pyridinylmethyl)sulfonyl]- (CA INDEX NAME)

